Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine

NCT03320174 is registered in ClinicalTrials.gov with 60 Degrees Pharmaceuticals LLC as lead sponsor.

NCT NCT03320174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03320174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Site, Randomized, Double Blind, Placebo-Controlled Study to Assess the Long-Term Safety of Tafenoquine
Lead sponsor
60 Degrees Pharmaceuticals LLC
Phase
Phase 2
Overall status
Completed
Start date
October 5, 2017
Completion date
July 13, 2021
Enrollment
600 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers